CD30 + Lymphoproliferative Disorders of the Skin
- 1 April 2017
- journal article
- review article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 31 (2) , 317-334
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- TCR-γ Expression in Primary Cutaneous T-cell LymphomasAmerican Journal of Surgical Pathology, 2013
- EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*Blood, 2011
- Prognosis of Lymphomatoid PapulosisThe Oncologist, 2006
- Cd30+ cutaneous lymphoproliferative disorders: The stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphomaJournal of the American Academy of Dermatology, 2003
- CD30 antigen expression in cutaneous inflammatory infiltrates of scabies: a dynamic immunophenotypic pattern that should be distinguished from lymphomatoid papulosisJournal of Cutaneous Pathology, 2002
- Gemcitabine-associated CD8+ CD30+ pseudolymphoma.British Journal of Dermatology, 2001
- Cefuroxime induced lymphomatoid hypersensitivity reactionPostgraduate Medical Journal, 2000
- Carbamazepine-induced lymphadenopathy mimicking Ki-1 (CD30 +) T-cell lymphomaPathology, 1997
- Systemic cytokine administration alters the histology of the eruption of lymphocyte recoveryJournal of Cutaneous Pathology, 1996
- Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disordersJournal of the American Academy of Dermatology, 1993